News: Merck & Co Inc (MRK.N)

MRK.N on New York Stock Exchange

45.99USD
17 May 2013
Price Change (% chg)

$-0.38 (-0.82%)
Prev Close
$46.37
Open
$46.26
Day's High
$46.70
Day's Low
$45.08
Volume
5,632,824
Avg. Vol
3,754,779
52-wk High
$48.78
52-wk Low
$37.02

Search Stocks
Select another date:

Thu, May 9 2013

Merck sales representative claims sexual bias, seeks over $100 million

- A sales representative for Merck & Co. filed a more than $100 million sex discrimination lawsuit against the drugmaker on Thursday, claiming that it particularly discriminates against pregnant employees and women with children.

Continue Reading

Merck sales rep alleges sexual bias, seeks over $100 mln

May 9 - A senior sales representative for Merck & Co has sued the drugmaker for more than $100 million, alleging the drugmaker discriminates against female employees in terms of pay and advancement, particularly pregnant employees and female employees with children.

FDA approves Merck combination cholesterol lowering pill

- The U.S. Food and Drug Administration approved a Merck & Co cholesterol lowering pill that combines a generic version of Pfizer Inc's Lipitor with its own Zetia, Merck said on Friday.

Fitch Affirms Merck & Co.'s IDR at 'A+'; Outlook Negative

(The following statement was released by the rating agency) CHICAGO, May 03 (Fitch) Fitch Ratings has affirmed Merck & Co.'s (Merck) ratings, including the Issuer Default Rating (IDR) at 'A+'. The Rating Outlook is revised to Negative from Positive. A full list of ratings affirmed is listed below. The ratings apply to approximately $20.5 billion in outstanding debt. KEY RATING DRIVERS Leveraging Share-Buybacks Pressure Credit Profile On April 1, Merck announced the expansion of its share re

Wall Street drops on data, earnings; Facebook up late

NEW YORK - Stocks fell sharply on Wednesday as the latest economic data continued a trend of indicators pointing to anemic growth while bellwether companies disappointed on revenue. | Video

Merck's Januvia diabetes drug lags, 2013 forecast cut

- Merck & Co Inc reported a surprising drop in quarterly sales of diabetes medicine Januvia, its biggest product and a frequent driver of quarterly earnings, and the drugmaker cut its full-year profit forecast on Wednesday.

UPDATE 3-Merck's Januvia diabetes drug lags, 2013 forecast cut

May 1 - Merck & Co Inc reported a surprising drop in quarterly sales of diabetes medicine Januvia, its biggest product and a frequent driver of quarterly earnings, and the drugmaker cut its full-year profit forecast on Wednesday.

US STOCKS-Wall St down on weak data, earnings; Fed on tap

* U.S. companies hire less, manufacturing growth slows in April

REFILE-US STOCKS SNAPSHOT - Wall St dips as Merck drags; Fed on tap

NEW YORK, May 1 - Wall Street edged lower at the open on Wednesday, weighed by weak results from Merck as investors waited to hear from the U.S. Federal Reserve on the state of the economy.

US STOCKS-Futures slip ahead of open on Merck, ADP; Fed on tap

* U.S. Fed expected to maintain $85 bln/month in bond buys

Select another date:

Press Releases

Search Stocks